In the safety analyses @ ( @ % ) of @ patients allocated to the levodopa-carbidopa intestinal gel group had adverse events ( five -LSB- @ % -RSB- serious ) , as did @ ( @ % ) of @ patients allocated to the immediate-release oral levodopa-carbidopa group ( seven -LSB- @ % -RSB- serious ) , mainly associated with the percutaneous gastrojejunostomy tube .